Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-Mesitran vs Fluconazole in Recurrent Vulvovaginal Candidiasis
NCT05367089Phase 3Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Aug 2022
- Primary completion
- Apr 2026
- Modality
- Hydrogel Systems, Transdermal Patches
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Revamil in recurrent vulvovaginal candidiasis (RVVC) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Vaginal swab culture result at 1 month. Started Aug 2022; status: recruiting.
02
Drugs
Revamil
03
Conditions
recurrent vulvovaginal candidiasis (RVVC)
Beyond the preview
Go deeper on NCT05367089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05367089.